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Patients with an implantable cardioverter-
defibrillator (ICD) may receive frequent shocks or
antitachycardia pacing for monomorphic ventricu-
lar tachycardia despite suppressive drug therapy.
Antitachycardia pacing is often well-tolerated but
not always effective. High voltage cardioversion is
usually painful and may cause severe, disabling
anxiety for some patients. Therefore, catheter ab-
lation is an important adjunct to medical ther-
apy for patients with structural heart disease who
have frequent shocks for episodes of ventricular
tachycardia. In 56–100% of selected patients,
hemodynamically-tolerated monomorphic ven-
tricular tachycardia can be successfully ablated
with radiofrequency energy and standard map-
ping techniques [1–6]. Herein we review the indi-
cations, benefits and risks of radiofrequency abla-
tion of monomorphic ventricular tachycardia for
patients with structural heart disease and an ICD.
Willems et al. [4] published the first series of pa-
tients with catheter ablation of monomorphic ven-
tricular tachycardia as an adjunct to ICD therapy.
Among 6 patients, 5 had monomorphic ventricu-
lar tachycardia originating in a healed myocar-
dial scar related to coronary artery disease and
the other patient had bundle branch reentry. Four
of 6 patients had incessant monomorphic ventric-
ular tachycardia at the time of the procedure and
the remaining 2 had frequent ICD shocks. The
monomorphic ventricular tachycardia in all pa-
tients was successfully ablated, but 2 of 6 patients
continued to have relatively frequent ICD shocks
during the follow-up period.
Results of RF Ablation for VT
Radiofrequency ablation of monomorphic ventric-
ular tachycardia decreases ICD shocks and im-
proves quality of life, as shown in a prospective
study of 21 consecutive patients with coronary
artery disease and a previous myocardial infarc-
tion [6]. Their mean ejection fraction was 22% and
they had failed an average of 2.5 suppressive
drugs; 16 of 21 were taking amiodarone at the time
of the ablation procedure and 18 of 21 were on mul-
tiple antiarrhythmic drugs. Antiarrhythmic medi-
cations were continued through the procedure and
indefinitely thereafter. The patients had received
an average of 17 shocks for monomorphic ventric-
ular tachycardia in the month before ablation and
one patient had received 54 shocks. Fourteen of
21 patients had spontaneous monomorphic ven-
tricular tachycardia(s) recorded on a 12-lead ECG
and the ventricular tachycardia cycle length was
available in the remainder of patients by stored
electrogram analysis from the ICD. An induced
monomorphic ventricular tachycardia was pre-
sumed to be clinically-important if it matched
the morphology and cycle length recorded on a
12-lead ECG or the cycle length alone in those
patients without 12-lead ECG documentation.
Twenty-six ventricular tachycardias in 21 patients
were felt to be responsible for clinical symptoms
prior to the ablation procedure. A total of 85 ven-
tricular tachycardias (range 1–15 per patient)
were inducible with a mean cycle length of 430 ms.
Twenty additional inducible ventricular tachycar-
dias were targeted for ablation besides the 26 ven-
tricular tachycardias felt to be responsible for the
majority of clinical symptoms. The remaining 39
ventricular tachycardias were poorly-tolerated
and could not be mapped.
The patients underwent an average of 1.4 proce-
dures and 12 radiofrequency energy applications.
The procedures lasted on average 93 minutes from
the onset of mapping to the last radiofrequency ap-
plication and averaged 50 minutes of fluoroscopy
time. The mapping techniques have been previ-
ously described and do not require sophisticated
mapping and recording systems [7,8]. Concealed
entrainment was the most useful criterion for a
successful radiofrequency application. Thirty-six
of 46 targeted monomorphic ventricular tachy-
cardias (78%) were successfully ablated. If the
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monomorphic ventricular tachycardia was well-
tolerated, the success rate was 89%. Sixteen of
21 patients had a successful procedure as defined
by elimination of the clinically-important mono-
morphic ventricular tachycardia (76%). A signif-
icant complication occurred in only one patient
who required a dual chamber pacemaker after a
successful ablation of a high septal monomorphic
ventricular tachycardia.
The average number of ICD therapies per
month for patients with an average follow-up time
of 1 year (range 1–32 months) was significantly de-
creased in the 16 patients who underwent a suc-
cessful ablation procedure (59 ± 80 vs. 0.5 ± 1, p =
0.01). Among the patients with unsuccessful pro-
cedures, the difference in monthly ICD therapies
did not reach statistical significance (358 ± 661
vs. 1.5 ± 2, p = 0.3). There were no predictors of a
successful ablation. A quality-of-life questionnaire
was distributed to all patients within 1 month of
the last follow-up date. The quality-of-life score
significantly improved for patients with a success-
ful procedure but not for patients with a failed
ablation.
Benefits of RF Ablation
The benefits of catheter ablation as an adjunct to
ICD therapy for patients with hemodynamically-
tolerated, and therefore, mappable monomorphic
ventricular tachycardia are clear from the results
of Strickberger et al. [6]. Patients with an acutely
successful ablation had fewer ICD therapies and
an improved quality of life. These patients were
carefully selected, however, to avoid the pitfalls
of attempting to ablate monomorphic ventricular
tachycardia that is hemodynamically poorly-
tolerated. Mapping the monomorphic ventricular
tachycardia using standard techniques circuit re-
quires hemodynamic stability for sustained peri-
ods while the catheter is manipulated to potential
ablation sites.
Newer mapping technology, such as non-contact
[9] or basket electrodes [10], may allow ablation
of hemodynamically poorly-tolerated ventricular
tachycardia by identifying a critical component of
the reentrant circuit during a few beats of ven-
tricular tachycardia. Since the last review, radio-
frequency ablation of hemodynamically poorly-
tolerated monomorphic ventricular tachycardia
has also proven to be effective in patients with
structural heart disease and an ICD during the
baseline rhythm [11]. Using fluoroscopy and a
magnetic mapping system (CARTO) to identify
scarred endocardium, linear radiofrequency
lesions were made between “dense scar” and ei-
ther anatomic boundaries or normal myocardium.
Twelve of 16 (75%) patients who had received mul-
tiple ICD shocks in the month prior to ablation
were free of ICD shocks during a median of
8 months follow-up time. This technique required
a relatively large number of mean lesions for acute
success (mean = 55). The volume of tissue criti-
cal to maintaining a reentrant circuit, however, is
small relative to the volume of scar tissue. Larger
and deeper lesions with future catheter technolo-
gies, such as cooled radiofrequency energy [12],
may also minimize the need for precise mapping,
although the complication rate may be higher and
the effects of large lesions on myocardial function
have not been carefully examined. Hopefully, new
technology or future refinements of existing tech-
nology will allow more precise location of criti-
cal circuits for hemodynamically poorly-tolerated
ventricular tachycardia so that the volume of tis-
sue requiring ablation is minimized.
One should consider catheter ablation for pa-
tients whose monomorphic ventricular tachycar-
dia is felt to be hemodynamically stable. In gen-
eral, these patients have a tachycardia cycle
length >300 ms and/or an absence of symptoms
to suggest profound hypotension, for example syn-
cope. In experienced hands with appropriate tech-
nology, hemodynamically poorly-tolerated ventric-
ular tachycardia also may be successfully ablated.
There are significant risks associated with
catheter ablation of monomorphic ventricular
tachycardia for patients with coronary artery dis-
ease. In the Strickberger series [6] no patients
died as a direct result of the ablation, and the
sole complication was heart block requiring a dual
chamber pacemaker. An earlier report of 15 pa-
tients from the University of Michigan reported
no deaths and no significant complications [1]. The
mortality rate in other published reports is as high
as 2% and other reported complications include
cardiac perforation and tamponade, stroke, my-
ocardial infarction, and femoral artery occlusion
[3,5]. The technique most successful in identifying
a critical portion of the monomorphic ventricular
tachycardia circuit is concealed entrainment. The
positive predictive value of a successful ablation
is improved if concealed entrainment is accom-
panied by a stimulus-QRS interval/ventricular
tachycardia cycle length ratio of ≤70%, a match
of the stimulus-QRS and electrogram-QRS inter-
vals, or isolated mid-diastolic potentials that can-
not be dissociated from the ventricular tachycar-
dia [8]. Post-pacing interval has also been shown
to be effective [2]. Endocardial activation time dis-
tinct from isolated diastolic potentials and pace-
mapping are generally of little additional benefit
to the criteria mentioned above [8]. Multiple mor-
phologies of monomorphic ventricular tachycardia
are frequently induced in patients with coronary
artery disease [1,3,6,7,11]. Although it is impor-
tant to target the monomorphic ventricular
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Table 1. Indications for RFA of VT in patients with ICD’s
Patient characteristics Frequent ICD shocks for VT refractory to AAD therapy
Intolerance to effective AAD therapy
Rhythms (e.g., sinus tachycardia) that overlap in rate with slow VT
VT characteristics Hemodynamically-tolerated or possibly poorly-tolerated at specialized centers
Inducible by programmed electrical stimulation
Incessant
Monomorphic
Abbreviations: RFA = radiofrequency ablation, VT = ventricular tachycardia, ICD = implantable cardioverter-defibrillator, AAD =
antiarrhythmic drug.
tachycardia which has been documented to occur
spontaneously, other hemodynamically-stable,
monomorphic ventricular tachycardias induced in
the electrophysiology laboratory are probably im-
portant to ablate since they may occur clinically
[11]. However, this has not been systematically
studied.
There is no information in the literature to
guide antiarrhythmic drug use following success-
ful catheter ablation of monomorphic ventricular
tachycardia. For patients who underwent an
acutely successful ablation in the University of
Michigan series [6], very few shocks were expe-
rienced during the follow-up period. All of these
patients, however, continued their antiarrhythmic
drugs. Until further evidence is available, patients
who are tolerant of appropriate antiarrhythmic
drug therapy should continue drug therapy follow-
ing an acutely successful procedure. Although not
statistically significant, some patients also seemed
to benefit despite an acute ablation failure. These
patients had antiarrhythmic drugs modified, but
it is possible that the myocardial substrate was
favorably altered such that antiarrhythmic drug
therapy was more efficacious.
Conclusion
Radiofrequency catheter ablation of hemodynam-
ically-stable monomorphic ventricular tachy-
cardia is an important adjunct to but not replace-
ment for medical therapy in carefully selected
patients with coronary artery disease and an
implantable cardioverter-defibrillator (Table 1).
The success rate is approximately 75% in experi-
enced hands and is associated with a low compli-
cation rate, fewer ICD therapies and an improved
quality-of-life.
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